Autopsy report · NCT05917470
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
Cause of deathOther
“Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year before it stopped.
- 21 participants enrolled.
- Results were posted on the registry 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Oncternal Therapeutics, Inc
- Sponsor type
- Industry
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ONCT-534
- Participants
- 21
- Sites
- 10
- Countries
- United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.